Variable | Total (n%) |
---|---|
Age (Years) | Â |
Mean ± SD | 51.61 ± 11.59 |
Range | 28–82 |
Breast cancer molecular subtype | Â |
HER2-enriched | 42 (29.2) |
Luminal A | 31 (21.5) |
Triple positive | 36 (25.0) |
Triple negative (TNBC) | 35 (24.3) |
Grade | Â |
I | 7 (4.9) |
II | 35 (24.3) |
III | 102 (70.8) |
Tumor volume (cm 3 ) | Â |
Mean ± SD | 41.00 ± 70.88 |
Range | 0.11-571.77 |
TNM Stage | Â |
I | 7 (4.9) |
II | 37 (25.7) |
III | 48 (33.3) |
IV | 49 (34.0) |
Undetermined | 3 (2.1) |
pT | Â |
T1 | 11 (7.6) |
T2 | 74 (51.4) |
T3 | 44 (30.6) |
T4 | 15 (10.4) |
pT | Â |
T1/T2 | 85 (59.0) |
T3/T4 | 59 (41.0) |
pN | Â |
N0 | 40 (27.8) |
N1 | 31 (21.5) |
N2 | 29 (20.1) |
N3 | 39 (27.1) |
Undetermined | 5 (3.5) |
M | Â |
M0 | 92 (63.9) |
M1 | 49 (34.0) |
Undetermined | 3 (2.1) |
Axillary lymph node metastasis | Â |
Negative | 41 (28.5) |
Positive | 101 (70.1) |
Undetermined | 2 (1.4) |
Lymphatic/vascular invasion | Â |
Negative | 47 (32.6) |
Positive | 91 (63.2) |
Undetermined | 6 (4.2) |
HR status | Â |
Negative | 77 (53.5) |
Positive | 67 (46.5) |
HER-2 status | Â |
Negative | 66 (45.8) |
Positive | 78 (54.2) |
DCIS | Â |
Absent | 32 (22.2) |
Present | 109 (75.7) |
Undetermined | 3 (2.1) |
Family history | Â |
No | 90 (62.5) |
Yes | 25 (17.4) |
Undetermined | 29 (20.1) |
SP | Â |
Low (TS ≤ 5) | 85 (59.0) |
High (TS > 5) | 59 (41.0) |
NK1R | Â |
Low (TS ≤ 1) | 91 (63.2) |
High (TS > 1) | 53 (36.8) |
Ki-67 | Â |
Low (≤ 22%) | 83 (57.6) |
High (> 22%) | 61 (42.2) |
PKM2 | Â |
Low (TS ≤ 4) | 78 (54.2) |
High (TS > 4) | 55 (38.2) |
Undetermined | 11 (7.6) |